The efficacy and safety of RC88 in patients with ovarian cancer, non-squamous-non-small-cell lung-carcinoma and cervical cancer: Results from a first-in-human phase 1/2 study
机构:[1]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China[2]Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属协和医院[3]Yunnan Cancer Hospital, Kunming, China[4]Chongqing University Cancer Hospital, Chongqing, China[5]Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[6]Shandong Cancer Hospital, Jinan, Shandong, China[7]Shandong Cancer Hospital, Jinan, China[8]Tianjin Medical University Cancer Institute and Hospital, Tianjin, China[9]Hubei Cancer Hospital, Wuhan, China[10]Hunan Cancer Hospital, Changsha, China[11]Qilu Hospital of Shandong University, Jinan, China[12]First Hospital of Jilin University, Changchun, China[13]Nanjing Drum Tower Hospital, Nanjing, China[14]Sichuan Cancer Hospital, Chengdu, China四川省肿瘤医院[15]RemeGen Co., Ltd., Yantai, China[16]School of Life Science and Technology, Tonji Univesity, Shanghai, China
第一作者机构:[1]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
推荐引用方式(GB/T 7714):
Yutao Liu,Guiling Li,Runxiang Yang,et al.The efficacy and safety of RC88 in patients with ovarian cancer, non-squamous-non-small-cell lung-carcinoma and cervical cancer: Results from a first-in-human phase 1/2 study[J].JOURNAL OF CLINICAL ONCOLOGY.2024,42(16):
APA:
Yutao Liu,Guiling Li,Runxiang Yang,Yu Huang,Suxia Luo...&Yuankai Shi.(2024).The efficacy and safety of RC88 in patients with ovarian cancer, non-squamous-non-small-cell lung-carcinoma and cervical cancer: Results from a first-in-human phase 1/2 study.JOURNAL OF CLINICAL ONCOLOGY,42,(16)
MLA:
Yutao Liu,et al."The efficacy and safety of RC88 in patients with ovarian cancer, non-squamous-non-small-cell lung-carcinoma and cervical cancer: Results from a first-in-human phase 1/2 study".JOURNAL OF CLINICAL ONCOLOGY 42..16(2024)